Finally, it can be concluded that targeting of the components of the PERK-dependent UPR signaling pathway via small-molecule PERK inhibitors, may contribute to the development of novel, innovative treatment strategies against rheumatoid arthritis. This evidence concerns the gene EIF2AK3 and rheumatoid arthritis.